Originally Posted by
Hancocks
The real test cost analysis is presently being undertaken by the Centers for Medicare & Medicaid Services (CMS) and the U.S. Department of Veterans Affairs (VA) that analysis will be about the cost savings identified by having clinicians use the CxBladder test. They will weigh it up against the various combinations of existing tests.
I personally consider a sign up from either of these two organisations as the next momentous announcements and validation of CxBladder and, something worth celebrating, obviously CMS (100 Million people) more so than VA (9 Million people). CxBladder is presently covered for ~130,000,000 Americans by these providers; MultiPlan, FedMed, ACPN & Stratose.
The CMS reimbursement for the Abbott Molecular – UroVysion (FISH) Procedure Code 88120 test varies from state to state and for the 2015 Code Map the range of figures are:
ALABAMA – Entire State
Medicare Reimbursement Amount: Global Fee $556.66
CALIFORNIA NORTH – San Francisco
Medicare Reimbursement Amount: Global Fee $850.42